Burkitt Lymphoma - Pipeline Review, H2 2016

Date: November 9, 2016
Pages: 124
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B74C8CCF881EN
Leaflet:

Download PDF Leaflet

Burkitt Lymphoma - Pipeline Review, H2 2016
Burkitt Lymphoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burkitt Lymphoma – Pipeline Review, H2 2016, provides an overview of the Burkitt Lymphoma (Oncology) pipeline landscape.

Burkitt lymphoma is a form of non-Hodgkin's lymphoma in which cancer starts in immune cells called B-cells. Symptoms include fever, night sweats, swollen lymph nodes and weight loss. The disease is more common in males and people with compromised immune systems, such as those with HIV/AIDS. Treatment includes chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burkitt Lymphoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Burkitt Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burkitt Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Burkitt Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 3 and 13 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.Burkitt Lymphoma.

Burkitt Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Burkitt Lymphoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Burkitt Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Burkitt Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Burkitt Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Burkitt Lymphoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Burkitt Lymphoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Burkitt Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Burkitt Lymphoma Overview
Therapeutics Development
Pipeline Products for Burkitt Lymphoma - Overview
Pipeline Products for Burkitt Lymphoma - Comparative Analysis
Burkitt Lymphoma - Therapeutics under Development by Companies
Burkitt Lymphoma - Therapeutics under Investigation by Universities/Institutes
Burkitt Lymphoma - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Burkitt Lymphoma - Products under Development by Companies
Burkitt Lymphoma - Products under Investigation by Universities/Institutes
Burkitt Lymphoma - Companies Involved in Therapeutics Development
AbbVie Inc
Arvinas, Inc.
bluebird bio, Inc.
Boehringer Ingelheim GmbH
Constellation Pharmaceuticals, Inc.
Immunomedics, Inc.
Karyopharm Therapeutics, Inc.
Millennium Pharmaceuticals Inc
Patrys Limited
Seattle Genetics, Inc.
Takeda Pharmaceutical Company Limited
Theravectys SA
Burkitt Lymphoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
19-3S - DRUG PROFILE
Product Description
Mechanism Of Action
R&D Progress
20-3S - DRUG PROFILE
Product Description
Mechanism Of Action
R&D Progress
alisertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARV-825 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bb-2121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target CD19 for ALL - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target CD30 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denintuzumab mafodotin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E1-3s - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Epstein-Barr virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibrutinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ixazomib citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugate to Target CD20 for Leukemia and Burkitt Lymphoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PATLM-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selinexor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SH-7129 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SH-7133 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SH-7139 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit BET for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
volasertib trihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Burkitt Lymphoma - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Burkitt Lymphoma, H2 2016
Number of Products under Development for Burkitt Lymphoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Burkitt Lymphoma - Pipeline by AbbVie Inc, H2 2016
Burkitt Lymphoma - Pipeline by Arvinas, Inc., H2 2016
Burkitt Lymphoma - Pipeline by bluebird bio, Inc., H2 2016
Burkitt Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Burkitt Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2016
Burkitt Lymphoma - Pipeline by Immunomedics, Inc., H2 2016
Burkitt Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
Burkitt Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Burkitt Lymphoma - Pipeline by Patrys Limited, H2 2016
Burkitt Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2016
Burkitt Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Burkitt Lymphoma - Pipeline by Theravectys SA, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Burkitt Lymphoma - Dormant Projects, H2 2016

LIST OF FIGURES

Number of Products under Development for Burkitt Lymphoma, H2 2016
Number of Products under Development for Burkitt Lymphoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Burkitt Lymphoma - Pipeline Review, H1 2016 US$ 2,000.00 May, 2016 · 115 pages
Follicular Lymphoma - Pipeline Review, H2 2015 US$ 1,700.00 Dec, 2015 · 478 pages
Acute Lymphoblastic Lymphoma - Pipeline Review, H2 2015 US$ 1,600.00 Sep, 2015 · 45 pages
T-Cell Lymphomas - Pipeline Review, H1 2014 US$ 1,500.00 Apr, 2014 · 132 pages
Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015 US$ 1,600.00 Feb, 2015 · 175 pages

Ask Your Question

Burkitt Lymphoma - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: